Developing efficient predictive models for the diagnosis of VEXAS syndrome
Daniel Montes(WinnMed), Matthew J. Koster(Mayo Clinic in Arizona), Abhishek A. Mangaonkar(Mayo Clinic), Horatiu Olteanu(Mayo Clinic in Arizona), Ronald S. Go(Mayo Clinic), Alexander Hines(WinnMed), Kenneth J. Warrington(Mayo Clinic), Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Kaaren K. Reichard(Mayo Clinic), Cynthia S. Crowson(Mayo Clinic), Megan M. Sullivan(Mayo Clinic in Arizona), Kambiz Kalantari(Mayo Clinic), Andrew C. Hanson(Mayo Clinic), Hannah E. Langenfeld(Mayo Clinic in Arizona), David S. Viswanatha(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 4
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
|Journal of Clinical Oncology|1999|697